Comparative efficacy and safety of vonoprazan- and rabeprazole-based triple therapy in second-line Helicobacter pylori eradication

Comparative efficacy and safety of vonoprazan- and rabeprazole-based triple therapy in second-line Helicobacter pylori eradication - Comparative efficacy and safety of vonoprazan- and rabeprazole-based triple therapy in second-line Helicobacter pylori eradication

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000060484

Enrollment

Registered

2026-01-27

Start date

2015-03-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

H. pylori infection

Interventions

Vonoprazan-based triple therapy in second-line H. pylori eradication Rabeprazole-based triple therapy in second-line H. pylori eradication

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients who received VPZ-based or RPZ-based triple therapy for second-line H. pylori eradication in Fuyoukai Murakami Hospital from 1 March 2015 to 28 February 2022

Exclusion criteria

Exclusion criteria: None

Design outcomes

Primary

Measure	Time frame
Second-line eradication rate	—

Secondary

Measure	Time frame
Treatment emergent adverse events	—

Countries

Japan

Contacts

Public ContactYusaku Kajihara

Fuyoukai Murakami Hospital Department of Gastroenterology

y_kaji2012@yahoo.co.jp+81-17-729-8888

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026